2 Thermo Fisher Way
127 articles with ViewRay Incorporated
ViewRay, Inc. announced financial results for the third quarter ended September 30, 2019..
Educational Event to Feature Presentations from MRIdian® Users and ESTRO Past President on the Strategic, Economic, Clinical and Technical Aspects of MRI-Guided Radiation Therapy
ViewRay, Inc. (NASDAQ: VRAY) today announced preliminary results for the third quarter 2019
Joint Cancer Program in Boston First in New England to Offer MRI-Guided Radiation Therapy
VRAY NOTICE: ROSEN, A LEADING LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against ViewRay, Inc.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of ViewRay, Inc. (NASDAQ: VRAY) from March 15, 2019 through August 8, 2019, inclusive (the "Class Period")
ViewRay, Inc. (NASDAQ: VRAY) announced today that Penn State Health has entered into a master agreement for the purchase of up to four MRIdian systems, placing an order for its first system today
Stanford Health Care to Acquire a ViewRay MRIdian System
Leading Radiation Oncology Meeting to Feature Unique Capabilities and Compelling Patient Outcomes with ViewRay's MRIdian
Clinicians from 17 Hospitals Worldwide to Present Clinical Experience with MRIdian MRI-Guided Radiation Therapy at ASTRO
ViewRay, Inc. announced that the Company will host a physician-led informational discussion for investors and analysts during the 2019 American Society of Radiation Oncology Annual Meeting in Chicago.
ViewRay Announces Results of the First Prospective Clinical Trial on MR-guided Radiation Treatment for Prostate Cancer Without Implanted Markers
ViewRay, Inc. (Nasdaq: VRAY) announced today the acceptance of publication by the International Journal of Radiation Oncology, Biology and Physics of the first prospective clinical trial of MR-guided radiation therapy (MRgRT) in patients with localized prostate cancer.
ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will participate in two upcoming investor conferences in New York, NY.
ViewRay, Inc. announced financial results for the second quarter ended June 30, 2019.
ViewRay Announces Conference Call and Webcast of Second Quarter 2019 Financial Results to be Held After Market on August 8, 2019
ViewRay, Inc. announced details relating to the release of its second quarter 2019 financial results.
ViewRay, Inc. announced the appointment of Dr. Gail Wilensky to its Board of Directors.
Leading Medical Physics Meeting to Feature More than 40 Presentations on ViewRay's MRIdian MRI-Guided Radiotherapy
Presentations Highlight MRIdian Clinical Experience with Real-Time On-Table Adaptive Radiotherapy at a Growing Number of Institutions Worldwide
Received 7 new orders for MRIdian systems totaling $42.8 million, compared to 3 orders totaling $21.2 million in the first quarter of 2018.
ViewRay Announces Conference Call and Webcast of First Quarter 2019 Financial Results to be Held After Market on May 2, 2019
ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2019 financial results.
ViewRay Announces Conference Call and Webcast of Fourth Quarter and Full Year 2018 Financial Results to be Held After Market on March 14, 2019
ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its fourth quarter and full year 2018 financial results.
Siteman Cancer Center Advances Precision Cancer Care through Presentations, Peer-Reviewed Publications and Pioneering Clinical Experience on its MRIdian Systems
ViewRay, Inc. today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2018. The preliminary results have not been audited and are subject to change.